Biosensor Detects Pancreatic Cancer Early Using Blood Samples – Medical Xpress

Brazilian researchers have developed an electrochemical biosensor capable of detecting pancreatic cancer in its early stages using a blood sample. The device identifies the biomarker CA19-9, which is associated with the disease, at low concentrations in patient blood samples. This approach offers a simpler and more affordable alternative to conventional diagnostic methods, which are often less accessible.

The biosensor works by using specific antibodies that bind to the CA19-9 protein. This binding alters the distribution of electrical charges on the electrode surface of the sensor. The device then translates this change into a measurable capacitance signal, allowing for the detection of the biomarker.

In tests conducted using 24 blood samples from patients, the sensor demonstrated its ability to detect the presence of pancreatic cancer. The research was carried out at the University of São Paulo, with the goal of enabling rapid and accessible diagnosis to improve treatment outcomes.

Pancreatic cancer is often asymptomatic in its early stages, which frequently leads to late diagnosis. This delay contributes to the disease having one of the lowest survival rates among cancers, with a five-year survival rate of only 3% in advanced cases. Early detection through accessible tools like this biosensor could significantly improve patient prognosis.

The development represents a step toward making cancer screening more widely available, particularly in regions where advanced medical infrastructure is limited. By focusing on a detectable biomarker in blood, the technology avoids the need for more invasive or expensive procedures.